CB heads into the back half of May in an uncommon spot for a mega-cap insurer — analysts are raising targets, short sellers are pulling back, and the stock is almost exactly where it was a month ago.
The most coherent story this week is on the positioning side. Short interest has been declining steadily. It dropped nearly 6% over the past month to roughly 0.9% of the free float — a level that barely registers as a short thesis. The direction of travel is clear: sellers who built positions through early-to-mid April, when estimated short shares climbed above 4.2 million, have been unwinding since late April. Days to cover has compressed to around 1.0, and borrowing costs have collapsed — cost to borrow fell more than 50% over the past month to just 0.23%. Availability is comfortably loose, all pointing to a lending market where demand to short CB has largely evaporated.
Options confirm the relaxed tone. The put/call ratio is running at 0.62, slightly below its 20-day average of 0.63 and well off its 52-week high of 0.95. That is roughly half a standard deviation below the recent mean — not a bullish extreme, but a signal that options traders have not felt the need to reach for downside protection. The 52-week PCR low of 0.46 shows there is room for positioning to get more constructive; right now it looks neutral, neither defensive nor aggressively bullish.
The Street has been more animated. After Chubb reported Q1 results on April 22, a cluster of analysts raised targets. Barclays lifted to $375, Citizens jumped to $365 from $350, and KBW nudged to $374 — all while maintaining existing ratings. Wells Fargo moved to $333 from $321 post-earnings, keeping an Equal-Weight. JPMorgan had already moved its target to $340 from $330 a few days before the print. The consensus remains a hold, with 13 hold ratings and two underperforms, but the direction of post-earnings revisions was upward across most of the firms that took action. At $324, the mean analyst target of around $350 implies low-single-digit upside, and CB's ORTEX analyst recommendation divergence factor ranks in the 100th percentile — an unusually wide gap between where the stock trades and where consensus sees fair value. BofA is the clearest outlier, maintaining an Underperform with a $271 target cut from $286 in mid-April. That is a significant discount to current price and represents the bear case in concentrated form.
The bull case rests on Chubb's diversified P&C franchise — strong combined ratios across commercial lines and a reinsurance book that has held up well. Bears point to softening in the property and financial lines market, management's deliberate reduction of large-account and E&S exposures, and the non-renewal of more than half of its large-account property book. Those concerns have not dented earnings enough to shift the majority of the Street, but they explain why more than a third of analysts are unwilling to go above hold. Valuation offers little excitement either way: the forward P/E is around 11.5x, the price-to-book near 1.5x, and both have been drifting slightly lower over the past 30 days as earnings estimates have not moved enough to re-rate the stock upward. The dividend score ranks in the 92nd percentile, a reminder that income-oriented holders have reason to stay.
The ownership picture adds its own weight to the stock. Berkshire Hathaway remains one of the two largest holders with a nearly 8.8% stake, last reported at end of 2025. Vanguard and BlackRock together account for more than 16% of shares. T. Rowe Price added roughly 3 million shares in the most recent quarter — the largest absolute change among the disclosed top holders — signalling at least one large active manager tilting more constructively. Insider activity, by contrast, has been uniformly on the sell side through February and March, though the volumes are modest relative to the float and the trades carry low significance scores. None suggest distress; they read as routine executive diversification.
The next focal point for CB is whether Q2 catastrophe loss estimates begin to weigh on the insurance sector into the summer. The stock spent almost all of April building and then patiently giving back a short interest overhang; the cleaner book that results leaves the price more directly exposed to underlying earnings and loss-ratio news from here.
See the live data behind this article on ORTEX.
Open CB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
